Clinical trials
Advanced Urothelial Cancer clinical trials
Below are recruiting advanced urothelial cancer clinical trials, each written for real people, not researchers. We’re tracking 104 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06904573RecruitingPhase 2
Probiotics for advanced bladder cancer
This trial tests if taking probiotics can help people with advanced bladder or urinary tract cancer that has spread. It's for those who have already tried immunotherapy. The goal is to see if probiotics can improve treatment outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06639347RecruitingPhase 1/Phase 2
Testing SHR-A2102 for advanced bladder cancer
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
Guangzhou, GuangdongAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT06120387Recruiting
Radiation after kidney-sparing surgery for high-risk ureteral cancer
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
BeijingAges 18 years+ - NCT06434350RecruitingPhase 1/Phase 2
Enfortumab vedotin and radiation for advanced bladder cancer
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
Houston, TexasAges 18 years+ - NCT07221942RecruitingPhase 2
Pembrolizumab and Enfortumab Vedotin for Advanced Bladder Cancer
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06598761Recruiting
Immunotherapy plus radiation after surgery for advanced UTUC
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
BeijingAges 18–80 - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT06892860RecruitingPhase 2
Comparing shorter vs longer chemo before immunotherapy for bladder cancer
This trial is testing whether 3 cycles of chemotherapy are as effective as 6 cycles before starting maintenance immunotherapy (avelumab) for people with advanced bladder cancer. The goal is to see if a shorter chemo course can reduce side effects while still controlling the cancer.
ParisAges 18 years+ - NCT07148128RecruitingPhase 1/Phase 2
Testing the safety of WEF-001 for KRAS-mutant cancers
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Dallas, TexasAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT06200155RecruitingPhase 2
Psilocybin therapy for advanced cancer patients with anxiety or depression
This trial tests whether a drug called psilocybin, given with therapy, can help people with advanced cancer who are feeling anxious or depressed. You must have a stable cancer and be willing to travel to Houston for treatment.
Houston, TexasAges 25 years+ - NCT04235777RecruitingPhase 1
Immunotherapy plus radiation for metastatic non-prostate genitourinary cancers
This Phase 1 study tests a new immunotherapy drug (bintrafusp alfa) alone or combined with another investigational antibody drug, plus stereotactic body radiation (SBRT), to treat metastatic genitourinary cancers that are not prostate cancer. It aims to find the safest dose and to see whether the combination can shrink tumors.
Bethesda, MarylandAges 18–120 - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT06683846RecruitingPhase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Advanced Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced urothelial cancer?
- Yes. Clin2 currently lists 104 recruiting advanced urothelial cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced urothelial cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced urothelial cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.